Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of June 30, 2024)

  • $167M

    TTM Revenue

  • $25-30M*

    Adj. EBITDA expected in 2024


    ~15%

    Adj. EBITDA
    Margin

  • $63M

    Cash balance

    with no debt

  • #1

    OA Pain
    U.S. Market Share


    ~25M

    Injections
    Worldwide

*Anticipate towards the lower end of range

Recent News
Sep 9, 2024

BEDFORD, Mass., September 9, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024,...

Aug 15, 2024

BEDFORD, Mass., August 15, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika...

Aug 8, 2024

Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating...

All Press Releases

Featured Event
Thursday, August 15, 2024
11:30am EDT

See All Events

Current Investor Presentation
Investor Contacts

Primary IR Contact

  • Mark Namaroff

    Vice President, Investor Relations, ESG, and Corporate Communications

    Anika Therapeutics, Inc.

    Phone: (781) 457-9287

    Email: investorrelations@anika.com

  • Transfer Agent

    Equiniti Trust Company LLC

    6201 15th Avenue

    Brooklyn NY 11219

    Phone: (800) 937-5449

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top